FDA Issues Final Guidance on Developing Gene Therapies for Neurodegenerative Diseases
November 1, 2022
Both clinical and surrogate endpoints are acceptable targets for trials investigating gene therapies (GT) for neurodegenerative diseases, according to finalized FDA guidance on developing these products.